The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow,Elias Campo,Stefano Pileri,Nancy L. Harris,Harald Stein,Reiner Siebert,Ranjana H. Advani,Michele Ghielmini,Gilles Salles,Andrew D. Zelenetz,Elaine S. Jaffe +10 more
TLDR
The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies.About:
This article is published in Blood.The article was published on 2016-05-19 and is currently open access. It has received 5321 citations till now.read more
Citations
More filters
Journal ArticleDOI
Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRI.
Katja N. De Paepe,Frederik De Keyzer,Pascal Wolter,Oliver Bechter,Daan Dierickx,Ann Janssens,Gregor Verhoef,Raymond Oyen,Vincent Vandecaveye +8 more
TL;DR: Correct staging and treatment initiation in malignant lymphoma depends on accurate lymph node characterization, however, nodal assessment based on conventional and diffusion‐weighted MRI remains challenging, particularly in smaller nodes.
Journal ArticleDOI
Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma
Mu-Chen Zhang,Ying Fang,Li Wang,Shu Cheng,Di Fu,Yang He,Yan Zhao,Chao-Fu Wang,Xu-Feng Jiang,Qi Song,Pengpeng Xu,Wei-Li Zhao +11 more
TL;DR: Relevance of DEL phenotype and molecular biomarkers on CR-CHOP response warrants further investigation in DLBCL, and the 2-year PFS and OS rates of double-expressor lymphoma phenotype (DEL) were improved, and negative prognostic effect of histone acetyltransferases CREBBP / EP300 mutations was also mitigated by CR- CHOP.
Journal ArticleDOI
Management of Anaplastic Large Cell Lymphoma
Dai Chihara,Michelle A. Fanale +1 more
TL;DR: Brentuximab vedotin (BV) is a standard treatment for relapsed/refractory ALCL; however, once the disease progresses in patients on BV, survival outcome is very poor, with a median overall survival of less than two months.
Journal ArticleDOI
Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs—a Swedish cohort study of risks by time, drug and lymphoma subtype
Karin Hellgren,Daniela Di Giuseppe,Karin E. Smedby,Christer Sundström,Johan Askling,Eva Baecklund +5 more
TL;DR: Treatment with bDMARDs, including both TNFi and non-TNFi bDMards, does not further increase the lymphoma risk in RA; instead, b DMARD treatment may actually reduce the excess lymphomarisk in RA.
Journal ArticleDOI
ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?
TL;DR: Combined with emerging functional studies, data suggest that ZEB1 and ZEB2 can act as tumor suppressors and/or oncogenes in blood borne malignancies, depending on the cellular context.
References
More filters
Book
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
TL;DR: Thank you very much for reading who classification of tumours of haematopoietic and lymphoid tissues, and maybe you have knowledge that, people have look hundreds of times for their chosen readings like this, but end up in malicious downloads.
Journal ArticleDOI
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
TL;DR: The criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly are addressed, and the issue of borderline categories having overlapping features with large B-cell lymphomas is reviewed.
Journal ArticleDOI
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente,Magda Pinyol,Víctor Quesada,Laura Conde,Gonzalo R. Ordóñez,Neus Villamor,Geòrgia Escaramís,Pedro Jares,Sílvia Beà,Marcos González-Díaz,Laia Bassaganyas,Tycho Baumann,Manel Juan,Mónica López-Guerra,Dolors Colomer,Jose M. C. Tubio,Cristina López,Alba Navarro,Cristian Tornador,Marta Aymerich,María Rozman,Jesús M. Hernández,Diana A. Puente,José M.P. Freije,Gloria Velasco,Ana Gutiérrez-Fernández,Dolors Costa,Anna Carrió,Sara Guijarro,Anna Enjuanes,Lluis Hernández,Jordi Yagüe,Pilar Nicolás,Carlos M. Romeo-Casabona,Heinz Himmelbauer,Ester Castillo,Juliane C. Dohm,Silvia de Sanjosé,Miguel A. Piris,Enrique de Alava,Jesús F. San Miguel,Romina Royo,Josep Lluís Gelpí,David Torrents,Modesto Orozco,David G. Pisano,Alfonso Valencia,Roderic Guigó,Mònica Bayés,Simon Heath,Marta Gut,Peter Klatt,John Marshall,Keiran Raine,Lucy Stebbings,P. Andrew Futreal,Michael R. Stratton,Peter J. Campbell,Ivo Gut,Armando López-Guillermo,Xavier Estivill,Emili Montserrat,Carlos López-Otín,Elias Campo +63 more
TL;DR: The patterns of somatic mutation, supported by functional and clinical analyses, strongly indicate that the recurrent NOTCH1, MYD88 and XPO1 mutations are oncogenic changes that contribute to the clinical evolution of the disease.
Journal ArticleDOI
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Steven P. Treon,Lian Xu,Guang Yang,Yangsheng Zhou,Xia Liu,Yang Cao,Patricia Sheehy,Robert Manning,Christopher J. Patterson,Christina K. Tripsas,Luca Arcaini,Geraldine S. Pinkus,Scott J. Rodig,Aliyah R. Sohani,Nancy L. Harris,Jason M. Laramie,Donald A Skifter,Stephen E Lincoln,Zachary R. Hunter +18 more
TL;DR: MYD88 L265P is a commonly recurring mutation in patients with Waldenström's macroglobulinemia that can be useful in differentiating WaldenStröm’s macrogalobulinesia and non-IgM LPL from B-cell disorders that have some of the same features.
Related Papers (5)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans,Dennis D. Weisenburger,Timothy C. Greiner,Randy D. Gascoyne,Jan Delabie,German Ott,H. Konrad Muller-Hermelink,Elias Campo,Rita M. Braziel,Elaine S. Jaffe,Zenggang Pan,Pedro Farinha,Lynette M. Smith,Brunangelo Falini,Alison H. Banham,Andreas Rosenwald,Louis M. Staudt,Joseph M. Connors,James O. Armitage,Wing C. Chan +19 more
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh,Michael B. Eisen,R. Eric Davis,Izidore S. Lossos,Andreas Rosenwald,Jennifer C. Boldrick,Hajeer Sabet,Truc Tran,Xin Yu,John Powell,Liming Yang,Gerald E. Marti,Troy Moore,James I. Hudson,Li-Sheng Lu,David B. Lewis,Robert Tibshirani,Gavin Sherlock,Wing C. Chan,Timothy C. Greiner,Dennis D. Weisenburger,James O. Armitage,Roger A. Warnke,Ronald Levy,Wyndham H. Wilson,M. R. Grever,John C. Byrd,David Botstein,Patrick O. Brown,Louis M. Staudt +29 more